国家神经系统疾病临床医学研究中心数据管理与共享系统

Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases

《国家中心数据管理与共享系统操作说明书 —— 研究者部分》

Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke: An Exploratory Analysis of the THALES Randomized Clinical Trial.

第一作者：Yongjun Wang, Yuesong Pan

通讯作者：Yongjun Wang

antiplatelet therapy; ischemic stroke

基本信息

2021-07-09

已发表文章

发表杂志：JAMA Neurology

发表类型: Article

影响因子(IF): 18.302

PMID: 34244703 Pubmed原文链接 全文下载

主要研究背景及目的

To evaluate the efficacy and safety of ticagrelor-aspirin in patients with moderate (NIHSS 4-5) ischemic stroke.

方法

The THALES (The Acute Stroke or Transient Ischemic Attack Treated With Ticagrelor and ASA for Prevention of Stroke and Death) trial was a randomized trial conducted at 414 hospitals in 28 countries in 2018/2019. This exploratory analysis compared stroke patients with baseline NIHSS 4-5 to those with NIHSS 0-3.

结论

Patients with a moderate ischemic stroke have consistent benefit from ticagrelor-aspirin versus aspirin alone as compared to patients with less severe ischemic stroke

主要结果

The observed primary-outcome event rate in patients with moderate stroke was 7.6% (129/1,671) on ticagrelor and 9.1% (150/1,641) on placebo (HR 0.84, 95% CI 0.66 to 1.06); and 4.7% (158/3,359) on ticagrelor and 5.7% (190/3,312) on placebo in those with less severe events at presentation (HR 0.82, 95% CI, 0.66 to 1.01) (P for interaction=.88).